Hepatitis B Virus News and Research

RSS

Stressgen granted new U.S. patent for treatment of Hepatitis B

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins, and methods of treating an HBV infection using these fusion proteins.

7 Sep 2005

Designer molecules that combine metals such as copper with natural organic materials could treat diseases in the body

That's the finding of chemists at Ohio State University, who have successfully tested such molecules against portions of HIV and Hepatitis C virus RNA in the laboratory. They've also created molecules that act like ACE, or angiotensin-converting enzyme, inhibitors - drugs that are used to lower blood pressure.

30 Aug 2005

Immunity - another important function of the mitochondria

Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.

28 Aug 2005

Susceptibility to Hepatitis A in patients with chronic liver disease due to Hepatitis C virus infection: missed opportunities for vaccination

A new study examining whether patients with chronic Hepatitis C virus (HCV) were routinely vaccinated against Hepatitis A virus (HAV) found that vaccination rates were low, even though HAV vaccination is recommended for patients with chronic liver disease.

23 Aug 2005

Study examines the incidence and risk factors associated with Hepatitis C infection in rural Egypt

The prevalence of antibodies to Hepatitis C Virus (HCV) in Egypt is among the highest in the world. From the 1950s until 1982 hundreds of thousands were infected during mass campaigns to control schistosomiasis (a parasitic disease) using mass therapy with intravenous antimony compounds, but little is known about current risk factors and rates of transmission.

23 Aug 2005

Genelabs drug discovery team advances compounds against the hepatitis C virus

Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.

4 Aug 2005

Molecular link between a viral infection and development of a common and fatal form of liver cancer

Researchers at The University of Texas M. D. Anderson Cancer Center have uncovered a crucial molecular link between a viral infection and development of a common and fatal form of liver cancer. In the process, they have identified a possible way to treat this disease as well as a number of other cancers.

26 Jul 2005

Crucial molecular link between a hepatitis B virus (HBV) and hepatocellular carcinoma (HCC)

21 Jul 2005

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

19 Jul 2005

Sirna Therapeutics granted new UK patents

Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).

12 Jul 2005

Studies compare hepatitis B drugs

According to a new study Roche's brand of interferon can help control the potentially deadly liver infection, hepatitis B, better than a competitor's drug.

30 Jun 2005

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Researchers at Johns Hopkins have uncovered how a majority of the genetic changes in the hepatic-C virus, the most common cause of liver disease, allow it to evade the body's immune system during infection.

10 Jun 2005

Scientists produce for the first time an infectious form of the hepatitis C virus in laboratory cultures of human cells

The finding, reported in the June 9 issue of Science Express, will allow scientists to study every stage of the HCV life cycle and develop drugs to treat this life-threatening disease that affects more than 170 million people around the world.

9 Jun 2005

Tobacco use persists after liver transplant for alcoholic liver disease

Alcohol and tobacco often go hand-in-hand. Studies have shown that approximately 90 percent of problem drinkers also smoke or chew tobacco. But tobacco use is not adequately addressed when patients undergo liver transplantation due to alcoholic liver disease, say authors of a new report.

26 May 2005

Study shows using expanded critera donors is safe

Patients who had received livers from hepatitis B virus core antibody (HBcAb) positive (indicates prior exposure to hepatitis B) and/or hepatitis C virus (HCV) positive donors had similar graft and patient survival compared to patients who received HBcAb negative or HCV negative livers, according to a study by the University of Pittsburgh's Thomas E. Starzl Transplantation Institute.

25 May 2005

Hepatitis B Virus News and Research

Stressgen granted new U.S. patent for treatment of Hepatitis B

Designer molecules that combine metals such as copper with natural organic materials could treat diseases in the body

Immunity - another important function of the mitochondria

Susceptibility to Hepatitis A in patients with chronic liver disease due to Hepatitis C virus infection: missed opportunities for vaccination

Study examines the incidence and risk factors associated with Hepatitis C infection in rural Egypt

Genelabs drug discovery team advances compounds against the hepatitis C virus

Molecular link between a viral infection and development of a common and fatal form of liver cancer

Crucial molecular link between a hepatitis B virus (HBV) and hepatocellular carcinoma (HCC)

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

Sirna Therapeutics granted new UK patents

Studies compare hepatitis B drugs

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Scientists produce for the first time an infectious form of the hepatitis C virus in laboratory cultures of human cells

Tobacco use persists after liver transplant for alcoholic liver disease

Study shows using expanded critera donors is safe

Benitec announces clinical candidate for the treatment of Hepatitis C

BMA calls for mass child vaccinations for hepatitis B virus (HBV)

Small number of genes can predict response to chronic hepatitis C therapy

New drug to treat chronic hepatitis B

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News